Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pf-06291874. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR known ✓ | P47871 | 10/20 | 1.00 |
| ▸ | GLP1R | P43220 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | GCG | P01275 | 13/20 | 0.88 |
| ▸ | GIPR | P48546 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-06291874 SCHEMBL11901097 | 1.00 | GCGR (1.00) | GCGRGLP1RCHRM5GCGGIPR | |
| Pf-06291874 SCHEMBL11900272 | 1.00 | GCGR (1.00) | GCGRGLP1RCHRM5GCGGIPR | |
| SCHEMBL11982222 | 0.94 | GCG (1.00) | GCGRGLP1RCHRM5GCGGIPR | |
| SCHEMBL15177069 | 0.94 | GCGR (0.88) | GCGRGLP1RCHRM5GCGGIPR | |
| SCHEMBL11901267 | 0.93 | GCGR (0.87) | GCGRGLP1RCHRM5GCGGIPR | |
| SCHEMBL11901266 | 0.93 | GCGR (0.87) | GCGRGLP1RCHRM5GCGGIPR | |
| SCHEMBL11962702 | 0.92 | GCGR (0.85) | GCGRGLP1RCHRM5GCGGIPR | |
| SCHEMBL11901197 | 0.92 | GCGR (0.85) | GCGRGLP1RCHRM5GCGGIPR | |
| SCHEMBL11962785 | 0.92 | GCG (1.00) | GCGRGLP1RCHRM5GCGGIPR | |
| SCHEMBL11962719 | 0.91 | GCGR (1.00) | GCGRGLP1RCHRM5GCGGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673260-B1 | GLUCAGON RECEPTOR MODULATOR | PFIZER (US) | 2016-08-17 | — | — | EP | claimed |
| EP-2673260-A1 | GLUCAGON RECEPTOR MODULATOR | Pfizer Inc (US) | 2013-12-18 | — | — | EP | claimed |
| US-8507533-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2013-08-13 | — | — | US | claimed |
| WO-2012107850-A1 | GLUCAGON RECEPTOR MODULATOR | PFIZER INC. (US) | 2012-08-16 | — | — | WO | claimed |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-08-09 | — | — | US | claimed |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20130296355-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER (US) | 2013-11-07 | — | — | US | disclosed |
| US-8507533-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507533-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507533-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2012107850-A1 | GLUCAGON RECEPTOR MODULATOR | PFIZER INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885GLP1R 1/4885CHRM5 1000/4885 |
| US-20130296355-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | GCGR 2/4885GLP1R 1/4885CHRM5 716/4885 |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | GCGR 2/4885GLP1R 1/4885CHRM5 716/4885 |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | GCGR 2/4885GLP1R 1/4885CHRM5 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.